![Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth - ScienceDirect Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827822001301-ga1.jpg)
Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth - ScienceDirect
![Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma | Gut Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma | Gut](https://gut.bmj.com/sites/default/files/highwire/gutjnl/71/3.cover-source.jpg)
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma | Gut
![Cancers | Free Full-Text | The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD Cancers | Free Full-Text | The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD](https://www.mdpi.com/cancers/cancers-13-00411/article_deploy/html/images/cancers-13-00411-g001.png)
Cancers | Free Full-Text | The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD
![Chronic Alcohol Use : Genetic Variations Provide Protection from Liver Cancer | Université Paris Cité Chronic Alcohol Use : Genetic Variations Provide Protection from Liver Cancer | Université Paris Cité](https://u-paris.fr/wp-content/uploads/2021/12/Foie-1920X1080.jpeg)
Chronic Alcohol Use : Genetic Variations Provide Protection from Liver Cancer | Université Paris Cité
![Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - UROONCO Kidney Cancer Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - UROONCO Kidney Cancer](https://kidney.uroonco.uroweb.org/wp-content/uploads/sites/8/RCC-logo-default-fb.png)
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - UROONCO Kidney Cancer
![Cancers | Free Full-Text | Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α Cancers | Free Full-Text | Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α](https://www.mdpi.com/cancers/cancers-12-02213/article_deploy/html/images/cancers-12-02213-g001.png)
Cancers | Free Full-Text | Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA
TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer - Archive ouverte HAL
![Jessica ZUCMAN-ROSSI | Professor (Full) | MD, PhD | Centre de Recherche des Cordeliers | Research profile Jessica ZUCMAN-ROSSI | Professor (Full) | MD, PhD | Centre de Recherche des Cordeliers | Research profile](https://i1.rgstatic.net/ii/profile.image/272438818766864-1441965884512_Q512/Jessica-Zucman-Rossi.jpg)
Jessica ZUCMAN-ROSSI | Professor (Full) | MD, PhD | Centre de Recherche des Cordeliers | Research profile
![Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response - ScienceDirect Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S001650851936771X-fx1.jpg)
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response - ScienceDirect
![Frontiers | The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective Frontiers | The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective](https://www.frontiersin.org/files/Articles/888850/fmed-09-888850-HTML/image_m/fmed-09-888850-g001.jpg)
Frontiers | The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective
![The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma | Request PDF The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma | Request PDF](https://i1.rgstatic.net/publication/345674594_The_pro-oncogenic_effect_of_the_lncRNA_H19_in_the_development_of_chronic_inflammation-mediated_hepatocellular_carcinoma/links/5fb27dce299bf10c3683e6d3/largepreview.png)